; and (2) by striking clauses (iv) through (ix) and inserting the following: (iv) For fiscal year 2020, $746,000,000. (v) For fiscal year 2021, $551,000,000. (vi) For each of fiscal years 2022 through 2024, $531,000,000. (vii) For fiscal year 2025, $536,000,000. (viii) For each of fiscal years 2026 through 2029, $531,000,000. . (b) FDA Activities Paragraph (4) of section 1002(b) of the 21st Century Cures Act ( Public Law 114–255 ) is amended to read as follows: (4) FDA activities The activities authorized to be funded under this section shall consist of the following, and of the total amounts authorized to be appropriated under paragraph (3) there are authorized to be appropriated to each category of activities a total amount not to exceed the following: (A) In addition to the allocations specified in subparagraphs (B) through (K), for the activities under subtitles A through F (including the amendments made by such subtitles) of title III of this Act and section 1014 of the Federal Food, Drug, and Cosmetic Act, as added by section 3073 of this Act: (i) For fiscal year 2020, $75,000,000. (ii) For fiscal year 2021, $70,000,000. (iii) For each of fiscal years 2022 through 2024, $50,000,000. (iv) For fiscal year 2025, $55,000,000. (v) For each of fiscal years 2026 through 2029, $50,000,000. (B) For modernization of the technical infrastructure of the Food and Drug Administration, including enhancements such as interoperability across the agency, and additional capabilities to develop an advanced information technology infrastructure to support the agency’s regulatory mission: (i) For fiscal year 2020, $300,000,000. (ii) For each of fiscal years 2021 through 2029, $200,000,000. (C) For support for continuous manufacturing of drugs and biological products, including complex biological products such as regenerative medicine therapies, through grants to institutions of higher education and nonprofit organizations and other appropriate mechanisms, for each of fiscal years 2020 through 2029, $50,000,000. (D) For support